DIHYDROSTREPTOMYCIN inj. BG 250 mg/ml Болгарія - болгарська - БАБХ (Българска агенция по безопасност на храните)

dihydrostreptomycin inj. bg 250 mg/ml

provet s. a. - Дигидрострептомицин (като сулфат Дигидрострептомицин) - инжекционен разтвор - 250 mg/ml - говеда, кози, кучета, овце, свине

Cabometyx Європейський Союз - болгарська - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Антинеопластични средства - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.